Supercentenarians have an abundance of cancer-killing immune cells
medicalxpress - The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. When a person gets sick, these cells multiply in a process called clonal expansion to help fight infect…
AI Summary: Analyses of people over 110 reveal an abundance of highly active cytotoxic immune cells capable of recognizing and eliminating cancerous cells, offering clues to extreme longevity. These hypervigilant immune profiles may explain low cancer rates among the very old and suggest immune‑based strategies that could one day mimic their natural defenses.
Charles Roberts Named the Next President and CEO of St. Jude Children’s Research Hospital
oncodaily - Charles Roberts, Current Cancer Center Director and Executive Vice-President and Next President and CEO of St. Jude Children’s Research Hospital, shared St. Jude Children’s Research Hospital’s post on LinkedIn, adding: […]
AI Summary: Charles Roberts was named president and CEO of St. Jude Children’s Research Hospital, stepping into leadership of a globally recognized pediatric cancer and research institution. He’ll oversee strategy, fundraising and clinical priorities as the center pursues ambitious research and care goals — and deal with the inevitable complexity of running a world-class nonprofit hospital.
ENZAMET: Enzalutamide Maintains Long-Term Survival Benefit in mHSPC
oncodaily - Treatment intensification with androgen receptor pathway inhibitors has become central to the management of metastatic hormone-sensitive prostate cancer (mHSPC). However, as patients remain on these therapies for years, longer follow-up […]
AI Summary: Long-term follow-up from ENZAMET shows enzalutamide continues to deliver a substantial overall survival benefit at eight years for patients with metastatic hormone-sensitive prostate cancer. The durable outcome cements enzalutamide’s role in combination androgen-deprivation strategies, giving patients and clinicians a proven option — not a cure, but progress that actually lasts.